Committee for Medicinal Products for Human Use (CHMP) Recommends Janumet(TM)(sitagliptin/metformin) for EU Approval for Type 2 Diabetes
WHITEHOUSE STATION, N.J.–(BUSINESS WIRE)–April 24, 2008–Merck
Sharp & Dohme (MSD) today received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP) recommending
European approval for Janumet(TM) (sitagliptin/metformin, MSD), a new
option for the treatment of type 2 diabetes. Sitagliptin/metformin
delivers substantial glucose lowering through a combination of
sitagliptin, an incretin enhancer (DPP-4 inhibitor), and metformin,
with a low […]